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1. Introduction
Prostate cancer has the highest incidence in the United States and the second highest in the
world among cancers in the male population. It is also one of the leading causes of cancer
deaths in males in the United States. Like other glandular organs, benign prostate has an
epithelial compartment containing mainly secretory luminal cells outlined with basal cells and
a stromal compartment including fibroblasts and smooth muscle cells. The development and
function of the prostate is mediated by circulating androgens which act via androgen receptor
(AR). Amongst the epithelial cells, AR is expressed only in secretory luminal cells, while in the
stroma, AR is expressed primarily by fibroblasts and smooth muscle cells in adulthood. In the
past, investigators mainly focused on studying epithelial AR function in prostate cancer,
defined the involved mechanisms and developed numerous hypotheses which have been
published and are widely accepted. However, limited data is available which can be used to
describe the function of stromal AR in prostate cancer. This review of the literature examines
the current knowledge and understanding of stromal AR function in prostate cancer and
endeavors to illustrate its translational significance.
2. Stromal cells in prostate carcinogenesis
The role of stromal cells on the initiation and promotion of carcinogenesis has been studied
over many years. This concept was pioneered from previous studies showing [1-3] that tumor
stroma, termed as CAF (cancer associated fibroblast), TAS (tumor associated stroma), or RS
(reactive stroma), is often different from the normal stroma [1]. Normal prostate stromal cells
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play a protective role and maintain growth quiescence within the prostatic tissue. Some
investigators have demonstrated in animal studies that when normal prostate stromal cells are
associated with malignant epithelial cells, there is a decrease in the proliferation rate [4,5] and
an apparent loss of former malignant properties of epithelial cells[6]. Some studies have also
shown restriction of growth of epithelial cells and induction into a more differentiated
phenotype [7]. Recombination studies using Dunning rat adenocarcinoma revealed that
normal stromal environment may override the effects of oncogenic mutations in tumor cells
[8]. Normal stromal cells therefore, retain properties of growth control and can prevent the
proliferation of cells undergoing neoplastic transformation.
Modification of stromal environment is necessary for carcinogenesis and it is adequately evi‐
dent on observation of stroma immediately adjacent to carcinoma cells in several tumors [1]. Re‐
combination experiments by viral transfection of oncogenes myc and ras into urogenital sinus
mesenchyme and epithelium have illustrated that changes are required in both epithelium and
stroma for prostatic carcinogenesis to occur [9]. The principal stromal cells – smooth muscle
cells and fibroblasts undergo a phenotype switching to emerge as myofibroblasts during tu‐
morigenesis. Morphologically and on the basis of cytoskeletal protein expression, myofibro‐
blasts are an intermediate between fibroblasts and smooth muscle cells [10,11].  They are
identified by increased expression of vimentin, alpha actin and decreased expression of calpo‐
nin and smooth muscle myosin. Other phenotypic changes seen in the cancer associated stro‐
ma include abnormal migratory behavior in vitro, alterations in the cell surface molecules,
expression of prostaglandin synthesizing enzymes, alterations in extra cellular matrix (ECM)
and altered expression of growth factors – platelet derived growth factor (PDGF), insulin-like
growth factor (IGF) 1 & 2, transforming growth factor beta 1(TGF-b1), hepatocyte growth fac‐
tor (HGF) and keratinocyte growth factor (KGF) [1]. There are several possible factors which
promote the modification of normal stromal cells into cancer associated stroma. Some signals
from epithelial cancer cells to surrounding stromal cells have been shown to alter the function
of stromal cells and ECM production, such as TGF-b1, which induces stromal secretion of ‘ver‐
sican’ an extracellular chondroitin sulfate proteoglycan [12]. In a hormone sensitive cell mod‐
el, variations in ECM have been shown to regulate stromal cell phenotype [13]. There is also
evidence that the genetic modifications seen in the cancer associated stroma [14] are a result of
epithelial to mesenchymal transitions of previously genetically abnormal epithelial cells. There
is a genome-wide change in stromal genes associated with prostate cancer. In an analysis by
Rowley et al. [15], when compared with normal stroma, a total of 544 unique genes were signif‐
icantly higher in the reactive stroma and 606 unique genes were lower. Gene ontology analysis
revealed significant alterations in a number of novel processes in prostate cancer reactive stro‐
ma, including neurogenesis, axonogenesis, and the DNA damage/repair pathways, as well as
an evidence of increased number of stem cells in prostate cancer reactive stroma.
Alternatively, in the ‘reactive stroma’ hypothesis [11] the stroma of prostate cancer has been
correlated with the granulation tissue in wound repair mechanism with reference to similar
biological responses. As in any wound repair situation the microenvironment would be
expected to be growth promoting which correlates with the promotion of survival and
proliferation of carcinoma cells by stroma in prostatic carcinogenesis. Tissue recombination
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studies have demonstrated that human prostatic tumor associated stroma can promote
carcinogenesis in genetically initiated human prostatic epithelial cells [1,16]. The results of this
experiment revealed an important inference that the cancer associated stroma, when formed,
exhibit a significant role in the epithelial cells promoting prostate carcinogenesis.
In contrast, some investigators [17] have shown that tumor associated stromal cells inhibit
epithelial cell growth by production of a specific inhibitory factor termed as prostatic epithe‐
lium inhibiting factor (PEIF). The expression of this factor by stromal cells was only in the
conditioned media collected from isolated stromal cell subcultures. Later in another experi‐
ment [18], stromal cells derived from surgically obtained prostatic carcinoma specimens were
co-cultured with PC-3 cells using double layer soft agar system. It was noticed that growth of
PC-3 cells was inhibited by the stromal cells.
The diversity in stromal cell function in inhibiting or promoting epithelial cell growth may be
explained by the heterogeneity of stromal cells in the stromal compartment. During carcino‐
genesis, the stromal cells display heterogeneity in their morphology as smooth muscle cells,
fibroblasts and myofibroblasts. Also, they are heterogenous in AR expression as AR positive
and AR negative cells. It may be possible that the presence and absence of AR in stromal cells
can dictate cancer epithelial cell proliferation or growth suppression.
3. Progressive loss of AR expression
Numerous studies have focused on AR expression in the epithelial cells during prostate
carcinogenesis and the progression of prostate cancer from primary to metastatic cancer and
from hormone sensitive to castration resistant prostate cancer (CRPC). It has been established
that epithelial AR is continuously expressed throughout prostate cancer disease progression.
Increased AR expression has been associated with aggressive disease and decreased progres‐
sion free survival (PFS) in patients [19].
The expression and function of stromal AR may be distinct from epithelial AR. As a result of
the structural, genetic and genomic [11,15] modifications of the stromal cells, there are
behavioral modifications expressed in tumor associated stroma. AR expression in stroma is
progressively decreased during the transition from benign tissue to cancer and during
progression of prostate cancer from low grade to high grade, primary to metastatic, hormone
sensitive to CRPC, as well as aggressive prostate cancer in African Americans.
In immunohistochemistry (IHC) studies, some investigators [20] found that AR expression
declines in the peri-epithelial stroma as early as in high grade prostatic intraepithelial neoplasia
(HGPIN) compared to normal prostate. In their analysis using tissue samples of HGPIN,
expression of AR was found to be absent in 80% and weak in 20% of peri-epithelial stromal
cell sections.
Analysis of stromal tissue of prostate cancer showed that loss of AR expression increased
linearly with higher histological grades in several studies. AR expression was absent in 67%
of peri-epithelial stromal tissue in well differentiated (Gleason score 2-4), 91% in moderately
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differentiated (Gleason score 5-7) and 94% in poorly differentiated (Gleason score 8-10)
prostate cancer [20]. In our study [21], we have shown a statistically significant decrease of
stromal AR expression (p < 0.001) in the areas of prostate cancer compared with benign prostate
with up to a 6% decrease in stromal AR expression. When stratified with Gleason score, we
established a trend of greater decrease of AR-positive stromal cells in cancerous areas com‐
pared to benign areas with increased tumor grade. Later on, other investigators have also
demonstrated that magnitude of loss of stromal AR is directly proportional to advanced
pathological stage along with higher Gleason scores [22]. By AR antibody immunostaining of
TURP (Trans Urethral Resection of Prostate) specimens obtained from patients with varying
Gleason scores and pathological stages, they found lower expression of AR in tumor stroma
compared to areas with normal stroma. This difference was notable (p < 0.05) in tumor
specimens of stage T2 and tumors with Gleason score of 7, while it was more statistically
significant (p <0.01) in tumor stage T3 and T4 and in specimens with Gleason score of 8-10.
Decreased stromal AR expression has also been correlated to disease progession including
metastasis and androgen-independence. Bergh et al. showed [22] that specimens with metastat‐
ic disease displayed significantly lower (p < 0.01) stromal AR expression. The AR staining was
only 1.6% in metastatic tumor stroma compared to 18 % in normal stroma which was equivalent
to a loss of expression by 11 fold. While in the non-metastatic disease specimens, the AR staining
was 13% in tumor stroma compared to 48 % in normal stroma, equivalent to a loss of expression
by 3.5 fold. Evidence is available [21] that during transition of prostate cancer from hormone
sensitive to CRPC, there is a significant decrease in stromal AR expression. AR levels were de‐
termined in the prostate stroma of 44 cases of hormone sensitive prostate cancer and in 22 cases
of CRPC by IHC analysis using affinity purified polyclonal AR antibodies. Scoring was per‐
formed by selecting three areas with 100 cells each in benign and cancerous regions in prostate
stromal tissue sections to determine the relative percentages of stromal cells that were AR-posi‐
tive and AR-negative, respectively. The levels of stromal AR expression were expressed as an
average percentage of AR-positive stromal cells. When comparing hormone sensitive and
CRPC tumor sections, a statistically significant 3-fold decrease of AR-positive stromal cells was
observed, from 4 % in hormone sensitive to 12 % in CRPC tumors. Most importantly, some in‐
vestigators have also reported an association of loss of stromal AR expression with clinical out‐
come or prostate cancer specific death in patients [25].
These studies suggest that there is a natural selection of stromal AR negative cells over AR
positive cells as the tumor progresses. With these results, we established that stromal AR
expression proportionately decreases as tumor grade increases and as cancer advances
towards metastatic and androgen independent disease. The mechanism behind the loss of AR
expression in the peri-epithelial stroma is not well understood. It has been attributed that
during the malignant transformation of epithelial cells, there is a shift in AR axis from stromal
cell dependent paracrine pathways to autocrine dependent pathways [23] and is increased
during tumor progression. When these cancer cells shift to autocrine mechanism of prolifera‐
tion, it appears that epithelial AR regulates a new series of genes for survival and proliferation,
not normally expressed by prostate epithelial cells [7]. The consequence of this may be that
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malignant epithelial cells no longer depend upon stromal-epithelial interactions and stromal
AR mediated growth factors for their survival and proliferation.
4. Stromal AR inhibits cancer epithelial cells
We  have  observed  and  previously  demonstrated  by  co-culture  experiments  using  well
characterized stromal cell  lines,  both in  vitro  and in  vivo  that,  in  the presence of  andro‐
gen,  stromal  cells  expressing  AR  decrease  the  growth  and  invasive  ability  of  prostate
cancer epithelial cells. It was hypothesized that this distinct effect of AR in stromal cells
is due to the involvement of paracrine factors/mechanisms regulated by both the epithe‐
lial and stromal cells.
The analysis was established [21] by using a well characterized prostate stromal cell line
morphologically similar to the tumor stroma. We constructed an immortalized stromal cell
line from prostate with BPH, termed as PShTert, stably expressing the human telomerase
catalytic subunit – hTert. Morphologically and ultra structurally, the cells expressed typical
characteristics of myofibroblasts. IHC showed diffuse, strongly positive stain for Vimentin
with a strong SMA staining in 25% of cells, and negative staining for Desmin. Together these
data support the myofibroblastic phenotype of the PShTert stromal cells. Western blot analysis
showed the absence of AR in these cell lines. We transduced this cell line with pBabeAR
retroviral vector and selected stable clonal cell lines expressing AR, termed as PShTertAR.
Functionality of the ectopic AR was confirmed by in vivo dual luciferase assay eliciting ligand
dependent transcriptional activation in the presence of androgens.
For in vitro analysis, transwell indirect co-culture assays using these two stromal cell lines with
PC3 cells were performed. In the presence of androgen, co-culture with PShTertAR resulted
in inhibition of PC3 cell proliferation compared to PC3 cell growth when cultured alone (p =
0.045). In contrast, co-culture with AR negative PShTert cells resulted in enhancement of
growth rate of PC3 cells compared to PC3 cells grown alone (p = 0.03). Flow cytometric analysis
revealed that PC3 cells co-cultured with PShTertAR showed 20% S-phase cells, decreased from
the 27% S-phase cells measured inPC3 cells co-cultured with PShTert cells. We examined the
expression of cell cycle genes, including cyclin A, cyclin B, p21 and p27, and the expression of
Skp2, and all were decreased in PC3 cells co-cultured with PShTertAR compared with PC3
cells co-cultured with PShTert cells.
However, with co-cultures in androgen free media, both PShTert and PShTertAR cells
stimulated the growth of PC3 cells. Similarly in vivo analysis by co-injecting PC3 cells with
PShTert subcutaneously in the flank region of nude male mice resulted in development of
tumors twice as large as when PC3 was injected alone. On the other side, co-injection of PC3
cells and PShTertAR cell line resulted in statistically significant reductions of tumor growth
and size.
There were two important observations drawn from the analysis. Firstly, both AR negative
and AR positive stromal cells promote growth of prostate cancer epithelial cells in the absence
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of androgen by secretion of a paracrine factor which is independent of AR. Secondly, AR
positive stromal cells secrete another paracrine factor which is growth inhibitory for prostate
cancer epithelial cells and is dependent on the presence of androgen and AR.
5. Conclusion
With reference to our hypothesis that AR positive stromal cells inhibit the growth of PC3 cells
in the presence of androgen, we also analyzed and found similar results while using LNCaP
cells. However, the magnitude of growth inhibition was less significant in LNCaP cells as
compared to PC3 cells.
Therefore, there is a need to re-identify the role of continued androgen deprivation therapy
(ADT) during progression to CRPC. It may be possible that due to androgen deprivation, the
growth promoting stromal effects counteract the apoptotic effects of androgen ablation on
epithelial cells. On the contrary, the growth inhibiting effects of the stromal AR are lost during
ADT. The permanent methods of androgen ablation such as surgical castration can be replaced
by reversible methods of castration such as medical castration with LHRH analogues. Inter‐
estingly, some investigators have even observed that using androgen replacement therapy
(ART) in metastatic CRPC displayed biochemical improvement in patients [24]. Newer
therapies targeting the prostate cancer stromal cells should be evaluated.
Acknowledgements
This study is supported by NIH 1U01CA149556-01, DOD PCRP (PC080010 and PC111624),
and NYUSOM Center of Excellence on Urologic Disease Fund to PL.
Author details
Mandeep Singh, Garrett  Daniels, Yirong  Li and Peng Lee*
*Address all correspondence to: peng.lee@nyumc.org
Department of Pathology and Urology, New York University School of Medicine, New
York, NY, USA
Advances in Prostate Cancer470
References
[1] Cunha, G. R, Hayward, S. W, & Wang, Y. Z. Role of stroma in carcinogenesis of the
prostate. Differentiation (2002). , 70, 473-85.
[2] Bosman, F. T, De Bruïne, A, Flohil, C, & Van Der Wurff, A. ten Kate J, Dinjens WW.
Epithelial-stromal interactions in colon cancer. International Journal of Developmen‐
tal Biology. (1993). , 37(1), 203-211.
[3] Seljelid, R, Jozefowski, S, & Sveinbjörnsson, B. Tumor stroma. Anticancer Research.
(1999). A): , 4809-22.
[4] Decosse, J. J, Gossens, C. L, Kuzma, J. F, & Unsworth, B. R. Breast cancer: induction
of differentiation by embryonic tissue. Science. (1973). , 181(4104), 1057-8.
[5] Decosse, J. J, Gossens, C, Kuzma, J. F, & Unsworth, B. R. Embryonic inductive tissues
that cause histologic differentiation of murine mammary carcinoma in vitro. Journal
of National Cancer Institute. (1975). , 54(4), 913-22.
[6] Cooper, M, & Pinkus, H. Intrauterine transplantation of rat basal cell carcinoma as a
model for reconversion of malignant to benign growth. Cancer Research. (1977). , 37,
2544-52.
[7] Arnold, J. T, & Isaacs, J. T. Mechanisms involved in the progression of androgen-in‐
dependent prostate cancers: it is not only the cancer cell’s fault. Endocrine Related
Cancer. (2002). Mar; , 9(1), 61-73.
[8] Hayashi, N, Sugimura, Y, Kawamura, J, Donjacour, A. A, & Cunha, G. R. Morpho‐
logical and functional heterogeneity in the rat prostatic gland. Biology of Reproduc‐
tion. (1991). Aug; , 45(2), 308-21.
[9] Thompson, T. C, Timme, T. L, Kadmon, D, Park, S. H, Egawa, S, & Yoshida, K. Ge‐
netic predisposition and mesenchymal-epithelial interactions in ras+myc-induced
carcinogenesis in reconstituted mouse prostate. Molecular Carcinogenesis. (1993). ,
7(3), 165-79.
[10] Gabbiani, G, Hirschel, B. J, Ryan, G. B, Statkov, P. R, & Majno, G. Granulation tissue
as a contractile organ. A study of structure and function. Journal of Experimental
Medicine. (1972). , 135(4), 719-34.
[11] Tuxhorn, J. A, Ayala, G. E, & Rowley, D. R. Reactive stroma in prostate cancer pro‐
gression. Journal of Urology. (2001). , 166, 2472-83.
[12] Sakko, A. J, Ricciardelli, C, Mayne, K, & Tilley, W. D. LeBaron RG, Horsfall DJ. Versi‐
can accumulation in human prostatic fibroblast cultures is enhanced by prostate can‐
cer cell-derived transforming growth factor beta1. Cancer Research. (2001). , 61(3),
926-930.
Expression and Function of Stromal Androgen Receptor in Prostate Cancer
http://dx.doi.org/10.5772/52425
471
[13] Arnold, J. T, Kaufman, D. G, Seppälä, M, & Lessey, B. A. Endometrial stromal cells
regulate epithelial cell growth in vitro: a new co-culture model. Human Reproduc‐
tion. (2001). , 16(5), 836-45.
[14] Macintosh, C. A, Stower, M, Reid, N, & Maitland, N. J. Precise microdissection of hu‐
man prostate cancers reveals genotypic heterogeneity. Cancer Research. (1998). ,
58(1), 23-28.
[15] Dakhova, O, Ozen, M, Creighton, C. J, Li, R, Ayala, G, Rowley, D, & Ittmann, M.
Global gene expression analysis of reactive stroma in prostate cancer. Clinical Cancer
Research. (2009). , 15(12), 3979-89.
[16] Olumi, A. F, Grossfeld, G. D, Hayward, S. W, Carroll, P. R, Tlsty, T. D, & Cunha, G.
R. Carcinoma-associated fibroblasts direct tumor progression of initiated human pro‐
static epithelium. Cancer Research. (1999). , 59(19), 5002-11.
[17] König, J. J, Romijn, J. C, & Schröder, F. H. Prostatic epithelium inhibiting factor
(PEIF): organ specificity and production by prostatic fibroblasts. Urological Research.
(1987). , 15(3), 145-149.
[18] Kooistra, A, Romijn, J. C, & Schröder, F. H. Stromal inhibition of epithelial cell
growth in the prostate; overview of an experimental study. Urological Research.
(1997). Supplement 2): S , 97-105.
[19] Li, R, Wheeler, T, Dai, H, Frolov, A, Thompson, T, & Ayala, G. High level of andro‐
gen receptor is associated with aggressive clinicopathologic features and decreased
biochemical recurrence-free survival in prostate: cancer patients treated with radical
prostatectomy. American Journal of Surgical Pathology. (2004). , 28(7), 928-34.
[20] Olapade-olaopa, E. O. MacKay EH, Taub NA, Sandhu DP, Terry TR, Habib FK. Ma‐
lignant transformation of human prostatic epithelium is associated with the loss of
androgen receptor immunoreactivity in the surrounding stroma. Clinical Cancer Re‐
search. (1999). , 5(3), 569-76.
[21] Li, Y, Li, C. X, Ye, H, Chen, F, Melamed, J, Peng, Y, Liu, J, Wang, Z, Tsou, H. C, Wei,
J, Walden, P, Garabedian, M. J, & Lee, P. Decrease in stromal androgen receptor asso‐
ciates with androgen-independent disease and promotes prostate cancer cell prolifer‐
ation and invasion. Journal of Cellular and Molecular Medicine. (2008). B): ,
2790-2798.
[22] Wikström, P, Marusic, J, Stattin, P, & Bergh, A. Low stroma androgen receptor level
in normal and tumor prostate tissue is related to poor outcome in prostate cancer pa‐
tients. Prostate. (2009). Jun 1; , 69(8), 799-809.
[23] Gao, J, Arnold, J. T, & Isaacs, J. T. Conversion from a paracrine to an autocrine mech‐
anism of androgen-stimulated growth during malignant transformation of prostatic
epithelial cells. Cancer Research. (2001). , 61(13), 5038-44.
[24] Morris, M. J, Huang, D, Kelly, W. K, Slovin, S. F, Stephenson, R. D, Eicher, C, Dela‐
cruz, A, Curley, T, Schwartz, L. H, & Scher, H. I. Phase 1 trial of high-dose exogenous
Advances in Prostate Cancer472
testosterone in patients with castration-resistant metastatic prostate cancer. European
Urology. (2009). , 56(2), 237-44.
[25] Grant BuchananFreemasons Foundation Centre for Men’s Health, The Bazil Hetzel
Institute for Translational Health Research, University of Adelaide, SA, Australia.
Expression and Function of Stromal Androgen Receptor in Prostate Cancer
http://dx.doi.org/10.5772/52425
473

